Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(2011) In Alzheimer Disease and Associated Disorders 25(1). p.63-72- Abstract
- In untreated patients with Alzheimer disease (AD) the functional ability is gradually lost. What happens to the patients after continuous long-term cholinesterase inhibitor (ChEI) treatment is less investigated. The objective of this study was to describe the longitudinal functional outcome and analyze factors affecting the outcome in ChEI-treated patients. In an open, 3-year, nonrandomized, prospective, multicenter study in a routine clinical setting, 790 patients were treated with either donepezil, rivastigmine, or galantamine. At baseline and every 6 months, they were assessed with several rating scales including Instrumental Activities of Daily Living (IADL), Physical Self-Maintenance Scale (PSMS), and Mini-Mental State Examination... (More)
- In untreated patients with Alzheimer disease (AD) the functional ability is gradually lost. What happens to the patients after continuous long-term cholinesterase inhibitor (ChEI) treatment is less investigated. The objective of this study was to describe the longitudinal functional outcome and analyze factors affecting the outcome in ChEI-treated patients. In an open, 3-year, nonrandomized, prospective, multicenter study in a routine clinical setting, 790 patients were treated with either donepezil, rivastigmine, or galantamine. At baseline and every 6 months, they were assessed with several rating scales including Instrumental Activities of Daily Living (IADL), Physical Self-Maintenance Scale (PSMS), and Mini-Mental State Examination (MMSE). A faster functional decline was associated with lower cognitive ability at baseline, older age, and the interaction of higher education and longer time in the study. The patients residing with a spouse or relative showed slower deterioration in IADL score. A higher mean dose of ChEI, regardless of drug agent, was also related to slower instrumental ADL decline. Prediction models for longitudinal functional outcome were provided. AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1688125
- author
- Wattmo, Carina LU ; Wallin, Åsa LU ; Londos, Elisabet LU and Minthon, Lennart LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, activities of daily living, cholinesterase inhibitors, longitudinal study, statistical models, disease progression.
- in
- Alzheimer Disease and Associated Disorders
- volume
- 25
- issue
- 1
- pages
- 63 - 72
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000287472000010
- pmid:20847636
- scopus:79952192664
- pmid:20847636
- ISSN
- 1546-4156
- DOI
- 10.1097/WAD.0b013e3181f5dd97
- language
- English
- LU publication?
- yes
- id
- 4ae23304-9272-4f58-bbb3-d5cb587b34f3 (old id 1688125)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20847636?dopt=Abstract
- date added to LUP
- 2016-04-01 13:05:30
- date last changed
- 2022-03-29 05:28:43
@article{4ae23304-9272-4f58-bbb3-d5cb587b34f3,
abstract = {{In untreated patients with Alzheimer disease (AD) the functional ability is gradually lost. What happens to the patients after continuous long-term cholinesterase inhibitor (ChEI) treatment is less investigated. The objective of this study was to describe the longitudinal functional outcome and analyze factors affecting the outcome in ChEI-treated patients. In an open, 3-year, nonrandomized, prospective, multicenter study in a routine clinical setting, 790 patients were treated with either donepezil, rivastigmine, or galantamine. At baseline and every 6 months, they were assessed with several rating scales including Instrumental Activities of Daily Living (IADL), Physical Self-Maintenance Scale (PSMS), and Mini-Mental State Examination (MMSE). A faster functional decline was associated with lower cognitive ability at baseline, older age, and the interaction of higher education and longer time in the study. The patients residing with a spouse or relative showed slower deterioration in IADL score. A higher mean dose of ChEI, regardless of drug agent, was also related to slower instrumental ADL decline. Prediction models for longitudinal functional outcome were provided. AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome.}},
author = {{Wattmo, Carina and Wallin, Åsa and Londos, Elisabet and Minthon, Lennart}},
issn = {{1546-4156}},
keywords = {{Alzheimer's disease; activities of daily living; cholinesterase inhibitors; longitudinal study; statistical models; disease progression.}},
language = {{eng}},
number = {{1}},
pages = {{63--72}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Alzheimer Disease and Associated Disorders}},
title = {{Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.}},
url = {{http://dx.doi.org/10.1097/WAD.0b013e3181f5dd97}},
doi = {{10.1097/WAD.0b013e3181f5dd97}},
volume = {{25}},
year = {{2011}},
}